Effectiveness of 8-week Treatment with Glecaprevir/Pibrentasvir in Treatment-naïve or -experienced HCV Patients: Results from an Observational Retrospective Study in Real-life Settings (ODYSSEY)
Journal of Gastrointestinal and Liver Diseases · 2024
DOI: 10.15403/jgld-5745 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Gastrointestinal and Liver Diseases, 2024. Verfasst von Anca Trifan und 17 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Gastroenterology and Hepatology, Iasi; University of Medicine and Pharmacy Grigore T. Popa Iasi, Romania. . ancatrifan@yahoo.com. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Benzimidazoles, Antiviral Agents, Sulfonamides. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and Aims: Pan-genotypic ribavirin-free oral direct-acting antivirals, including the glecaprevir/pibrentasvir combination, are recommended for the treatment of most patients with chronic hepatitis C virus (HCV) infection. In Romania, the HCV-infected patient population receiving glecaprevir/pibrentasvir is not well characterized and data on treatment effectiveness is lacking. The ODYSSEY study aimed to provide insights into the characteristics and treatment outcomes of HCV-infected Romanian patients receiving 8-week therapy with glecaprevir/pibrentasvir.
Methods
This observational, retrospective medical chart review study was based on a Patient Support Program for HCV-infected patients (HCV-PSP) attending clinical practices in Romania and initiating glecaprevir/pibrentasvir between 01 February 2022 and 11 July 2023. Patients ≥18 years of age with compensated liver disease F0-F4 fibrosis grade treatment-naïve or F0-F3 fibrosis grade treatment-experienced on previous interferon-based regimens from the HCV-PSP were included in the ODYSSEY study. Patients received glecaprevir/pibrentasvir for at least 8 weeks. Sustained virological response (SVR) was assessed at 12 weeks after the 8-week treatment (SVR12). Analyses were conducted on the core population (CP) and the CP with sufficient follow-up data (CPSFU).
Results
The CP and CPSFU included 2,240 and 2,165 patients, respectively. In both populations, most patients were female (≥67.57%), aged >50 years (≥73.62%), and treatment-naïve (≥96.47%). F4 fibrosis was reported in 19% of patients. Hypertension was the most common relevant comorbidity, reported for 21% of patients; comorbidity rates increased with age. Overall SVR12 rates were 96.1% [95% confidence interval (CI): 95.2-96.8%) and 99.3% (95%CI: 98.9–99.6) in the CP and CPSFU, respectively. When stratified by gender, age category, comorbidities or fibrosis grade, SVR12 rates were >92% in the CP [except for the subgroups of patients with chronic kidney disease (87.5%) and depressive-/anxiety disorders (86.2%)] and ≥97.0% in the CPSFU. SVR12 rates were higher in female patients. In an exploratory analysis, in the CPSFU, the presence of diabetes mellitus [odds ratio (OR)=3.840; 95%CI: 1.093–13.495] and cardiovascular diseases (OR=7.904; 95%CI: 1.719-36.346) were associated with an increased probability to detect HCV RNA at 12 weeks post-treatment.
Conclusions
The 8-week treatment with glecaprevir/pibrentasvir resulted in high SVR12 rates for multiple HCV-infected patient profiles encountered in real-life settings in Romania.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Gastroenterology and Hepatology, Iasi; University of Medicine and Pharmacy Grigore T. Popa Iasi, Romania. . ancatrifan@yahoo.com.
- Institute of Gastroenterology and Hepatology, Iasi; University of Medicine and Pharmacy Grigore T. Popa Iasi, Romania. stanciucarol@yahoo.com.
- National Institute of Infectious Diseases Prof. Dr. Matei Bals, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. astreinucercel@yahoo.com.
- Dr. Victor Babes Clinical Hospital of Infectious and Tropical Diseases, Bucharest, Romania. augustinaculinescu@yahoo.com.
- Sf. Cuvioasa Parascheva Clinical Hospital of Infectious Diseases, Galati; Faculty of Medicine and Pharmacy, Dunărea de Jos University of Galati, Romania. lilibaroiu@yahoo.com.
- Sf. Apostol Andrei County Clinical Emergency Hospital, Constanţa; Faculty of Medicine, Ovidius University Constanţa, Romania. eugen.dumitru@yahoo.com.
Zitieren
APA
Trifan, A., Stanciu, C., Streinu-Cercel, A., Culinescu, A., Baroiu, L., Dumitru, E., Pojoga, C., Brisc, C., Brisc, M. M., Gheonea, D. I., Florescu, D. N., Pop, C. S., Diaconu, L. S., Munteanu, L., Iliescu, L., Diculescu, M., Ester, C., & Gheorghe, L. (2024). Effectiveness of 8-week Treatment with Glecaprevir/Pibrentasvir in Treatment-naïve or -experienced HCV Patients: Results from an Observational Retrospective Study in Real-life Settings (ODYSSEY). Journal of Gastrointestinal and Liver Diseases. https://doi.org/10.15403/jgld-5745
Vancouver
Trifan A, Stanciu C, Streinu-Cercel A, Culinescu A, Baroiu L, Dumitru E, et al. Effectiveness of 8-week Treatment with Glecaprevir/Pibrentasvir in Treatment-naïve or -experienced HCV Patients: Results from an Observational Retrospective Study in Real-life Settings (ODYSSEY). Journal of Gastrointestinal and Liver Diseases. 2024. doi:10.15403/jgld-5745
BibTeX
@article{Trifan2024,
author = {Trifan, Anca and Stanciu, Carol and Streinu-Cercel, Adrian and Culinescu, Augustina and Baroiu, Liliana and Dumitru, Eugen and Pojoga, Cristina and Brisc, Ciprian and Brisc, Mihaela Mihaela and Gheonea, Dan Ionut and Florescu, Dan Nicolae and Pop, Corina Silvia and Diaconu, Laura Sorina and Munteanu, Laura and Iliescu, Laura and Diculescu, Mircea and Ester, Carmen and Gheorghe, Liliana},
title = {Effectiveness of 8-week Treatment with Glecaprevir/Pibrentasvir in Treatment-naïve or -experienced HCV Patients: Results from an Observational Retrospective Study in Real-life Settings (ODYSSEY)},
journal = {Journal of Gastrointestinal and Liver Diseases},
year = {2024},
doi = {10.15403/jgld-5745}
}
EUVIMED